Welcome to our dedicated page for Fulgent Genetics news (Ticker: FLGT), a resource for investors and traders seeking the latest updates and insights on Fulgent Genetics stock.
Fulgent Genetics, Inc. (FLGT) delivers innovative genetic testing and diagnostic solutions through its dual focus on clinical laboratory services and oncology therapeutic development. This news hub provides investors and healthcare professionals with timely updates on the company’s financial performance, scientific advancements, and strategic initiatives.
Access authoritative reporting on earnings announcements, regulatory milestones, and partnership developments alongside analysis of FLGT’s expanding test menu and cancer research programs. Our curated news collection enables efficient tracking of operational updates across both laboratory services and drug development segments.
Key content includes coverage of diagnostic technology innovations, clinical trial progress, and healthcare collaborations that shape FLGT’s position in precision medicine. All materials are vetted for relevance to investment analysis and clinical practice trends.
Bookmark this page for streamlined access to Fulgent Genetics’ latest corporate developments, with new content added as official announcements are released through regulatory channels and company communications.
Fulgent Genetics, Inc. (NASDAQ: FLGT) will release its first quarter 2023 financial results on May 5, 2023, before the market opens. The company will hold a conference call at 8:30 AM ET to discuss these results and address questions from investors. Fulgent operates in two primary sectors: a clinical diagnostic business providing molecular and genetic testing, and a therapeutic development segment focused on cancer treatment through innovative drug delivery methods. The company aims to transition from a genomic diagnostics provider to a fully integrated precision medicine firm.
Mission Bio has partnered with Fulgent Genetics (NASDAQ: FLGT) to enhance drug development and clinical research. This collaboration allows Fulgent Genetics to offer single-cell multi-omics services using the Tapestri Platform, which includes a comprehensive menu of genomic analyses such as whole genome, RNA sequencing, and liquid biopsy.
This partnership is positioned to accelerate biomarker discovery and improve patient stratification in clinical trials. The Tapestri Platform's unique ability to analyze both genotype and phenotype at the single-cell level may unveil new treatment resistance mechanisms. This strategic move reflects the growing demand for precise clinical data, which is crucial for advancing precision oncology.
Fulgent Genetics (NASDAQ: FLGT) reported its financial results for 2022, with total revenue of $619.0 million and fourth-quarter revenue of $67.7 million. Core revenue soared 95% year-over-year to $181.5 million, indicating strong growth in its clinical and therapeutic business sectors. However, the company reported a GAAP loss of $23.8 million in Q4, resulting in a loss of $0.80 per share. For 2023, Fulgent projects a total revenue of approximately $240.0 million and anticipates a GAAP loss of $2.50 per share. The company emphasizes its focus on sustainable growth, particularly in oncology and reproductive health.
FAQ
What is the current stock price of Fulgent Genetics (FLGT)?
What is the market cap of Fulgent Genetics (FLGT)?
